Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Receivables: 2011-2023

Historic Receivables for Abeona Therapeutics (ABEO) over the last 9 years, with Jun 2023 value amounting to $5.7 million.

  • Abeona Therapeutics' Receivables fell 79.67% to $5.7 million in Q2 2023 from the same period last year, while for Jun 2023 it was $67.2 million, marking a year-over-year increase of 39.55%. This contributed to the annual value of $6.0 million for FY2021, which is N/A change from last year.
  • Per Abeona Therapeutics' latest filing, its Receivables stood at $5.7 million for Q2 2023, which was down 79.06% from $27.3 million recorded in Q3 2022.
  • Abeona Therapeutics' 5-year Receivables high stood at $28.2 million for Q2 2022, and its period low was $15,000 during Q3 2019.
  • In the last 3 years, Abeona Therapeutics' Receivables had a median value of $16.7 million in 2021 and averaged $16.8 million.
  • Per our database at Business Quant, Abeona Therapeutics' Receivables plummeted by 99.89% in 2019 and then surged by 93,233.33% in 2020.
  • Quarterly analysis of 5 years shows Abeona Therapeutics' Receivables stood at $15,000 in 2019, then spiked by 93,233.33% to $14.0 million in 2020, then reached $6.0 million in 2021, then reached $27.3 million in 2022, then slumped by 79.67% to $5.7 million in 2023.
  • Its Receivables was $5.7 million in Q2 2023, compared to $27.3 million in Q3 2022 and $28.2 million in Q2 2022.